Synergistic neutralization of pertussis toxin by a bispecific antibody in vitro and in vivo

Clinical and Vaccine Immunology

Volumn 23, Issue 11, 2016, Pages 851-862

  Wagner, Ellen K ^a   Wang, Xianzhe ^b   Bui, Andre ^b   Maynard, Jennifer A ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PERTUSSIS TOXIN; EPITOPE; IMMUNOGLOBULIN G;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CHO CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; TOXIN ANALYSIS; ANIMAL; ANTIBODY COMBINING SITE; BORDETELLA PERTUSSIS; CHEMISTRY; CRICETULUS; DRUG POTENTIATION; HAMSTER; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; SERODIAGNOSIS; WHOOPING COUGH;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES, ANTIBODY; BORDETELLA PERTUSSIS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; IMMUNOGLOBULIN G; MICE; NEUTRALIZATION TESTS; PERTUSSIS TOXIN; WHOOPING COUGH;

EID: 84995747161     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00371-16     Document Type: Article

References (60)

1. World Health Organization. 2012. Causes of death, worldwide. Global Health Observatory data repository. WHO, Geneva, Switzerland.
2. Australian Government Department of Health. 2003. Notifiable diseases surveillance, 1917 to 1991. Australian Government Department of Health, Canberra, Australia.
3. Spokes PJ, Quinn HE, McAnulty JM. 2010. Review of the 2008-2009 pertussis epidemic in NSW: notifications and hospitalisations. N S W Public Health Bull 21:167-173. http://dx.doi.org/10.1071/NB10031.
4. Sheridan SL, Frith K, Snelling TL, Grimwood K, McIntyre PB, Lambert SB. 2014. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Rev Vaccines 13:1081-1106. http://dx.doi.org/10.1586/14760584.2014.944167.
5. Mooi FR, Van Der Maas NAT, De Melker HE. 2014. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect 142:685-694. http://dx.doi.org/10.1017/S0950268813000071.
6. Andreasen C, Carbonetti NH. 2008. Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice. Infect Immun 76:5139-5148. http://dx.doi.org/10.1128/IAI.00895-08.
7. Winter K, Zipprich J, Harriman K, Murray EL, Gornbein J, Hammer SJ, Yeganeh N, Adachi K, Cherry JD. 2015. Risk factors associated with infant deaths from pertussis: a case-control study. Clin Infect Dis 61: 1099-1106. http://dx.doi.org/10.1093/cid/civ472.
8. Storsaeter J, Hallander HO, Gustafsson L, Olin P. 2003. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21:3542-3549. http://dx.doi.org/10.1016/S0264-410X(03)00407-9.
9. Nguyen AW, Wagner EK, Laber JR, Goodfield LL, Smallridge WE, Harvill ET, Papin JF, Wolf RF, Padlan EA, Bristol A, Kaleko M, Maynard JA. 2015. A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough. Sci Transl Med 7:316ra195. http://dx.doi.org/10.1126/scitranslmed.aad0966.
10. Corti D, Kearns JD. 2016. Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease. Curr Opin Immunol 40:51-61. http://dx.doi.org/10.1016/j.coi.2016.03 .001.
11. Kong R, Louder MK, Wagh K, Bailer RT, DeCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR. 2015. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol 89:2659-2671. http://dx.doi.org/10.1128/JVI.03136-14.
12. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 99:11346-11350. http://dx.doi.org/10.1073/pnas.172229899.
13. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther- Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53. http://dx.doi.org/10.1038/nature13777.
14. FDA Center for Drug Evaluation and Research. 2013. Guidance for industry: codevelopment of two or more new investigational drugs for use in combination. FDA Center for Drug Evaluation and Research, Silver Spring, MD.
15. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P. 2008. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974-977. http://dx.doi.org/10.1126/science.1158545.
16. Digiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu X, Suzich JA, Stover CK. 2014. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6:262ra155. http://dx.doi.org/10.1126/scitranslmed.3009655.
17. Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. 2016. Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell 165:1609-1620. http://dx.doi.org/10.1016/j.cell.2016.04.050.
18. Ridgway JBB, Presta LG, Carter P. 1996. "Knobs-into-holes" engineering of antibodyCH3domains for heavy chain heterodimerization. Protein Eng 9:617-621. http://dx.doi.org/10.1093/protein/9.7.617.
19. Smith K, Garman L, Wrammert J, Zheng N-Y, Capra JD, Ahmed R, Wilson PC. 2009. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 4:372-384. http://dx.doi.org/10.1038/nprot.2009.3.
20. Labrijn AF, Meesters JI, de Goeij BECG, van den Bremer ETJ, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PHC, van de Winkel JGJ, Schuurman J, Parren PWHI. 2013. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 110:5145-5150. http://dx.doi.org/10.1073/pnas.1220145110.
21. Sutherland JN, Maynard JA. 2009. Characterization of a key neutralizing epitope on pertussis toxin recognized by the monoclonal antibody 1B7. Biochemistry 48:11982-11993. http://dx.doi.org/10.1021/bi901532z.
22. Sivasubramanian A, Sircar A, Chaudhury S, Gray J. 2009. Toward high-resolution homology modeling of antibody Fv regions and application of antibody-antigen docking. Proteins 74:497-514. http://dx.doi.org/10.1002/prot.22309.
23. Lyskov S, Chou F, Conchuir S, Der B, Drew K, Kuroda D, Xu J, Weitzner B, Renfrew P, Sripakdeevong P, Borgo B, Havranek J, Kuhlman B, Kortemme T, Bonneau R, Gray J, Das R. 2013. Serverification of molecular modeling applications: the Rosetta Online Server That Includes Everyone (ROSIE). PLoS One 8:e63906. http://dx.doi.org/10.1371/journal.pone.0063906.
24. Duhovny D, Nussinov R, Wolfson H. 2002. Efficient unbound docking of rigid molecules, p 185-200. In Algorithms in bioinformatics. Lecture notes in computer science, vol 2452. Springer Verlag, Berlin, Germany. http://dx.doi.org/10.1007/3-540-45784-4-14.
25. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. 2005. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 33:W363-W367.
26. Stein PE, Boodhoo A, Armstrong GD, Heerze LD, Cockle SA, Klein MH, Read RJ. 1994. Structure of a pertussis toxin-sugar complex as a model for receptor binding. Nat Struct Biol 1:591-596. http://dx.doi.org/10.1038/nsb0994-591.
27. Friguet B, Chaffotte AF, Ohaniance LD, Goldberg ME. 1985. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 77: 305-319. http://dx.doi.org/10.1016/0022-1759(85)90044-4.
28. Stevens FJ. 1987. Modification of an ELISA-based procedure for affinity determination: correction necessary for use with bivalent antibody. Mol Immunol 24:1055-1060. http://dx.doi.org/10.1016/0161-5890 (87)90073-3.
29. Gillenius P, Jaatmaa E, Askelof P, Granstrom M, Tiru M. 1985. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biol Stand 13:61-66. http://dx.doi.org/10.1016/S0092-1157(85)80034-2.
30. Sato H, Sato Y, Ohishi I. 1991. Comparison of pertussis toxin (PT)- neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies. Infect Immun 59:3832-3835.
31. Millen SH, Watanabe M, Komatsu E, Yamaguchi F, Nagasawa Y, Suzuki E, Monaco H, Weiss AA. 2015. Single amino acid polymorphisms of pertussis toxin subunit S2 (PtxB) affect protein function. PLoS One 10:e0137379. http://dx.doi.org/10.1371/journal.pone.0137379.
32. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
33. Sato Y, Ito A, Ohishi I. 1987. Effect of monoclonal antibody to pertussis toxin on toxin activity. Infect Immun 55:909-915.
34. Kowalsky CA, Faber MS, Nath A, Dann HE, Kelly VW, Liu L, Shanker P, Wagner EK, Maynard JA, Chan C, Whitehead TA. 2015. Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing. J Biol Chem 290:26457-26470. http://dx.doi.org/10.1074/jbc.M115.676635.
35. Zhang X, Zhang L, Tong H, Peng B, Rames MJ, Zhang S, Ren G. 2015. 3D structural fluctuation of IgG1 antibody revealed by individual particle electron tomography. Sci Rep 5:9803. http://dx.doi.org/10.1038/srep09803.
36. Stanfield RL, Zemla A, Wilson IA, Rupp B. 2006. Antibody elbow angles are influenced by their light chain class. J Mol Biol 357:1566-1574. http://dx.doi.org/10.1016/j.jmb.2006.01.023.
37. Spiess C, Zhai Q, Carter PJ. 2015. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 67:95-106. http://dx.doi.org/10.1016/j.molimm.2015.01.003.
38. Williams AJ, Giese G, Persson J. 2015. Improved assembly of bispecific antibodies from knob and hole half-antibodies. Biotechnol Prog 31:1315-1322. http://dx.doi.org/10.1002/btpr.2130.
39. Elliott JM, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, Eigenbrot C, Scheer JM. 2014. Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction. J Mol Biol 426:1947-1957. http://dx.doi.org/10.1016/j.jmb .2014.02.015.
40. Ionescu RM, Vlasak J, Price C, Kirchmeier M. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97:1414-1426. http://dx.doi.org/10.1002/jps.21104.
41. Reichert JM. 2015. Therapeutic monoclonal antibodies approved or in review in the European Union or United States. The Antibody Society, Framingham, MA.
42. Reichert JM. 2016. Antibodies to watch in 2016. MAbs 8:197-204. http://dx.doi.org/10.1080/19420862.2015.1125583.
43. Morrison C. 2015. Antibacterial antibodies gain traction. Nat Rev Drug Discov 14:737-738. http://dx.doi.org/10.1038/nrd4770.
44. The IMpact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531-537. http://dx.doi.org/10.1542/peds.102.3.531.
45. Tsai C, Morris S. 2015. Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration "animal rule." Front Microbiol 6:1320. http://dx.doi.org/10.3389/fmicb.2015.01320.
46. US Food and Drug Administration. 2016. FDA approves new treatment for inhalation anthrax. FDA news release. FDA, Silver Spring, MD.
47. Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, McFarland EJ, Safrit JT, Graham BS, Snow W. 2014. HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. PLoS Med 11:e1001616. http://dx.doi.org/10.1371/journal.pmed.1001616.
48. Hazes B, Read RJ. 1997. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 36:11051-11054. http://dx.doi.org/10.1021/bi971383p.
49. Vance DJ, Tremblay JM, Mantis NJ, Shoemaker CB. 2013. Stepwise engineering of heterodimeric single domain camelidVHHantibodies that passively protect mice from ricin toxin. J Biol Chem 288:36538-36547. http://dx.doi.org/10.1074/jbc.M113.519207.
50. Herrera C, Klokk TI, Cole R, Sandvig K, Mantis NJ. 2016. A bispecific antibody promotes aggregation of ricin toxin on cell surfaces and alters dynamics of toxin internalization and trafficking. PLoS One 11:e0156893. http://dx.doi.org/10.1371/journal.pone.0156893.
51. Rhoden JJ, Dyas GL, Wroblewski VJ. 2016. A modeling and experimental investigation of the effects of antigen density, binding affinity, and antigen expression ratio on bispecific antibody binding to cell surface targets. J Biol Chem 291:11337-11347. http://dx.doi.org/10.1074/jbc .M116.714287.
52. Ngundi MM, Meade BD, Little SF, Quinn CP, Corbett CR, Brady RA, Burns DL. 2012. Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action. Clin Vaccine Immunol 19:731-739. http://dx.doi.org/10.1128/CVI.05714-11.
53. Martin SW, Pawloski L, Williams M, Weening K, Debolt C, Qin X, bReynolds L, Kenyon C, Giambrone G, Kudish K, Miller L, Selvage D, Lee A, Skoff TH, Kamiya H, Cassiday PK, Tondella ML, Clark TA. 2015. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis 60:223-227. http://dx.doi.org/10.1093/cid/ciu788.
54. Carbonetti NH, Artamonova GV, Mays RM, Worthington ZEV. 2003. Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect Immun 71:6358-6366. http://dx.doi.org/10.1128/IAI.71.11.6358-6366.2003.
55. Weiss AA, Hewlett EL, Myers GA, Falkow S. 1984. Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis. J Infect Dis 150:219-222. http://dx.doi.org/10.1093/infdis/150.2.219.
56. Williams M, Sen K, Weigand M, Skoff T, Cunningham V, Halse T, Tondella M, CDC Pertussis Working Group. 2016. Bordetella pertussis strain lacking pertactin and pertussis toxin. Emerg Infect Dis 22:319-322. http://dx.doi.org/10.3201/eid2202.151332.
57. Rasmussen SK, Naested H, Muller C, Tolstrup AB, Frandsen TP. 2012. Recombinant antibody mixtures: production strategies and cost considerations. Arch Biochem Biophys 526:139-145. http://dx.doi.org/10.1016/j.abb.2012.07.001.
58. Spiess C, Merchant M, Huang A, Zheng Z, Yang N-Y, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, Scheer JM. 2013. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 31:753-758. http://dx.doi.org/10.1038/nbt.2621.
59. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, Hansen-Estruch C, Chamberlain AK, Truhlar SM, Conner EM, Atwell S, Kuhlman B, Demarest SJ. 2014. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 32:191-198. http://dx.doi.org/10.1038/nbt.2797.
60. Saphire EO, Parren PWHI, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. 2001. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293:1155-1159. http://dx.doi.org/10.1126/science .1061692.